THU-237
Increasing prevalence of indications to choose bone/renalfriendly
antiviral drug: A territory-wide study of 135, 414 patients
from 2000 to 2017
Grace Lai-Hung Wong1, Becky Wing-Yan Yuen1, Yee-Kit Tse2,
Hester Wing-Sum Luk1, Terry CF Yip1, Henry Chan1,
VincentWai-SunWong1. 1The Chinese University of Hong Kong, Shatin,
Hong Kong; 2The Chinese University of Hong Kong, Shatin, Hong Kong
Email: [email protected]
Background and aims: The latest clinical practice guideline from
European Association for the Study of the Liver (EASL) published in
2017 advocate the use of entecavir or tenofovir alafenamide (TAF)
over tenofovir disoproxil fumarate (TDF) according to age, bone
disease and renal alteration. As patients with chronic hepatitis B
(CHB) are ageing with improved survival under better healthcare,
more patients may fulfil these criteria. We aimed to determine the
prevalence of these criteria in the territory-wide CHB cohort in Hong
Kong over 18 years from year 2000 to 2017.
Method: CHB patients who have been under the care at primary,
secondary and tertiary medical centers in the public sector in Hong
Kong were identified through the Clinical Data Analysis and
Reporting System of the Hospital Authority. The demographics and
prevalence of relevant bone and renal co-morbidities, and relevant
laboratory parameters were determined according to patients’ first
appearance in four time periods: 2000-2004, 2005-2009, 2010-2013
and 2014-2017.
Results: 136, 414 CHB patients were included. The prevalence of the
above criteria increased over the four periods: age >60 years 11.6%,
20.4%, 27.6% and 35.4%; Steroid/medications that worsen bone
density 57.2%, 50.5%, 56.0% and 61.8% respectively; albuminuria
0.2% 0.4% 0.7% and 1.1% respectively, and low phosphate (<2.5 mg/dl)
3.9%, 4.0%, 5.1% and 7.0% respectively (all P < 0.001; Figure).
Conclusion: CHB patients are getting older with increasing prevalence
of indications to choose entecavir or TAF over TDF according to
the latest EASL guidelines.
Funding: This work was supported by the Investigator Sponsored
Research of Gilead Sciences (Reference: IN-US-988-5290).作者: StephenW 时间: 2019-4-7 12:43